MarketCatalyst
← Back to Resources
Earnings

Arrowhead Pharmaceuticals Misses Fiscal Q4 2026 Estimates as Revenue Falls 85% to $37.8M

Revenue of $37.8M vs. $61.2M expected and adjusted EPS of -$3.04 vs. -$1.52; revenue down 85% from a year earlier.

Published Nov 12, 2026 · 4:41 PM ET · 2 min read

Arrowhead Pharmaceuticals (ARWR) missed estimates for the fiscal fourth quarter of 2026 on both revenue and adjusted EPS. Revenue was $37.8 million, down 85% from a year earlier, below the $61.2 million estimate, and adjusted EPS was -$3.04, down 1589% from a year earlier, below the -$1.52 estimate.

Shares fell 0.7% in after-hours trading as of 4:40 p.m. ET, to $46.83 from a $47.15 close.

-$3.04
Adjusted EPS, down 1589% YoY vs. -$1.52 estimate
$37.8M
Revenue, down 85% YoY vs. $61.2M estimate
-0.7%
Shares after hours as of 4:40 p.m. ET

Fiscal Q4 2026 scorecard

ParametersExpectedActualBeat/Miss
Adjusted EPS-$1.52-$3.04Miss by 100%
Revenue$61.2M$37.8MMiss by 38%
ChangeYoYQoQ
Adjusted EPS▼ 1589%▼ 124%
Revenue▼ 85%▼ 50%

By our calculation, revenue was $23.4 million below the estimate and adjusted EPS was $1.52 below it. The QoQ column compares with the previous quarter's revenue of $75.3 million and adjusted EPS of -$1.36. The YoY column compares with $256.5 million and -$0.18 in the same quarter a year earlier.

Track record

  • EPS record. Adjusted EPS beat the estimate in 2 of the last 8 reports, including this one.
  • Revenue record. Revenue beat the estimate in 4 of the last 8 reports.
  • Revenue trend. Revenue over the last 5 reports, oldest first: $256.5 million, $264.0 million, $73.7 million, $75.3 million and $37.8 million.

What to watch

  • Next-quarter estimates. Consensus calls for EPS of -$1.37 and revenue of $45.8 million next quarter, based on 5 analysts.
  • Revenue growth. Whether revenue stabilizes after this quarter's 85% decline from a year earlier to $37.8 million.
  • Estimate record. Whether Arrowhead Pharmaceuticals returns to beating EPS estimates, which it did in 2 of its last 8 reports.
  • Related coverage. See our reports on Dlocal, Erasca, Nektar Therapeutics and QXO.

Sources: Results are from Arrowhead Pharmaceuticals's Nov. 12, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Arrowhead Pharmaceuticals's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.

Readers also read

MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.